• Home
  •  / Ionis Pharmaceuticals

Ionis Pharmaceuticals

OverviewSuggest Edit

Ionis Pharmaceuticals discovers and develops RNA-targeted therapeutics. It provides an antisense technology platform designed to treat complicated and rare diseases. The Company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients.

TypePublic
Founded1989
HQCarlsbad, CA, USMap
Websiteionispharma.com
Employee Ratings3.5More
Overall CultureFMore
View Jobs (44)

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2020)817(+11%)
Job Openings44
Revenue (FY, 2020)$729.3 M(-35%)
Share Price (Mar 2021)$45(+5%)
Cybersecurity ratingAMore

Key People/Management at Ionis Pharmaceuticals

C. Frank Bennett

C. Frank Bennett

Executive Vice President, Chief Scientific Officer
Brett P. Monia

Brett P. Monia

Chief Executive Officer & Director
Onaiza Cadoret-Manier

Onaiza Cadoret-Manier

Executive Vice President, Chief Corporate Development and Commercial Officer
Elizabeth L. Hougen

Elizabeth L. Hougen

Executive Vice President, Finance and Chief Financial Officer
Eric E. Swayze

Eric E. Swayze

Executive Vice President, Research
Patrick R. O'Neil

Patrick R. O'Neil

Executive Vice President, Legal & General Counsel, Chief Compliance Officer
Show more

Ionis Pharmaceuticals Office Locations

Ionis Pharmaceuticals has an office in Carlsbad
Carlsbad, CA, US (HQ)
2855 Gazelle Ct
Show all (1)

Ionis Pharmaceuticals Financials and Metrics

Ionis Pharmaceuticals Revenue

Ionis Pharmaceuticals's revenue was reported to be $729.26 m in FY, 2020
USD

Revenue (FY, 2020)

729.3m

Gross profit (FY, 2020)

717.3m

Gross profit margin (FY, 2020), %

98.4%

Net income (FY, 2020)

(486.8m)

EBIT (FY, 2020)

(172.1m)

Market capitalization (29-Mar-2021)

6.3b

Closing stock price (29-Mar-2021)

45.0

Cash (31-Dec-2020)

397.7m

EV

6.3b
Ionis Pharmaceuticals's current market capitalization is $6.3 b.
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

108.5m99.1m102.0m147.3m214.2m283.7m346.6m507.7m599.7m1.1b729.3m

Revenue growth, %

45%32%22%

Cost of goods sold

1.8m4.4m11.9m

Gross profit

597.9m1.1b717.3m
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

23.5m28.6m21.1m24.8m20.7m23.2m47.3m11.6m43.4m38.1m23.6m28.2m57.1m44.1m62.6m120.4m49.1m36.9m38.5m110.9m110.3m104.2m120.9m144.4m117.7m145.4m297.2m163.8m167.9m133.4m145.5m160.1m

Cost of goods sold

1.0m1.4m967.0k2.5m3.0m3.1m

Gross profit

296.2m162.4m166.9m130.8m142.5m157.0m

Gross profit Margin, %

100%99%99%98%98%98%
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

70.1m65.5m124.5m160.0m143.0m128.8m84.7m129.6m278.8m683.3m397.7m

Accounts Receivable

51.1m

Prepaid Expenses

7.1m5.4m8.7m7.5m15.7m14.8m72.3m102.5m139.8m

Inventories

7.5m8.6m18.2m22.0m
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

46.0m100.1m86.2m85.0m55.3m56.4m85.6m84.6m107.7m296.5m256.4m161.8m94.1m73.2m148.3m119.5m126.6m93.3m112.5m84.3m114.2m133.0m159.2m227.5m805.5m479.9m375.8m272.5m247.9m486.2m530.2m633.1m

Prepaid Expenses

7.0m6.3m7.4m7.6m7.6m7.4m5.7m7.8m8.1m5.8m7.4m9.8m8.6m8.4m13.2m29.9m29.1m17.4m17.3m15.2m25.9m51.5m48.9m62.1m77.0m97.1m98.7m102.1m118.8m

Inventories

8.4m11.1m19.4m22.9m

Current Assets

536.9m507.6m437.4m410.7m377.1m347.6m350.4m361.6m431.8m669.1m763.3m722.1m705.8m681.2m835.4m855.5m868.3m763.9m698.0m730.3m962.4m964.4m1.1b1.1b2.1b2.1b2.4b2.4b2.4b2.6b2.5b2.5b
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(61.3m)(84.8m)(65.5m)(60.6m)(39.0m)(88.3m)(86.6m)(17.3m)215.0m303.3m(486.8m)

Depreciation and Amortization

4.8m6.6m7.1m6.6m6.4m7.0m7.5m6.7m12.5m14.5m15.4m

Inventories

284.0k(1.7m)(2.0m)(1.9m)1.7m(609.0k)(590.0k)(2.5m)1.4m(5.4m)(1.3m)

Accounts Payable

1.3m875.0k1.3m66.0k4.8m9.2m(10.7m)1.8m(655.0k)(16.3m)(2.8m)
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(34.8m)(47.3m)(20.0m)(37.9m)(64.8m)(24.0m)(25.2m)(62.8m)(1.7m)(11.8m)(31.3m)(43.4m)(70.0m)(16.7m)18.9m(16.8m)(62.9m)(119.8m)(112.4m)3.5m(7.7m)(12.6m)(10.8m)(67.4m)(87.7m)90.9m80.9m99.3m(58.5m)(102.2m)(145.3m)

Depreciation and Amortization

1.6m3.1m4.8m1.6m3.4m5.2m1.8m3.7m5.6m2.0m4.0m6.1m2.4m4.9m7.7m3.5m7.2m10.5m3.7m7.4m11.2m

Inventories

496.0k257.0k948.0k(549.0k)(492.0k)(293.0k)379.0k(769.0k)(2.4m)688.0k985.0k(962.0k)922.0k915.0k1.6m(2.5m)(5.7m)(6.6m)(2.2m)(3.0m)(1.5m)

Accounts Payable

(2.6m)2.0m1.4m(2.7m)(8.2m)862.0k(11.4m)(12.4m)(15.2m)472.0k(10.0m)(1.7m)(13.1m)(14.2m)(13.6m)(17.2m)(16.1m)(18.8m)411.0k(14.9m)(11.0m)
show all
USDQ2, 2010

Financial Leverage

2.3 x
Show all financial metrics

Ionis Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

Learn more about our premium products
SecurityScorecard logo

Ionis Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Ionis Pharmaceuticals Online and Social Media Presence

Ionis Pharmaceuticals's Trends

Embed Graph

Ionis Pharmaceuticals Company Culture

  • Overall Culture

    F

    45/100

  • CEO Rating

    D-

    60/100

  • Compensation

    A+

    95/100

Learn more on Comparably

Ionis Pharmaceuticals News and Updates

March 29, 2021

Thinking about trading options or stock in Marathon Digital, Ionis Pharmaceuticals, MicroStrategy, Apple, or Boeing?

NEW YORK, March 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MARA, IONS, MSTR, AAPL, and BA. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...
March 03, 2021

What’s Happening With Ionis Pharmaceuticals Stock?

In December 2020 we talked about how Ionis Pharmaceuticals stock seems to be oversold, and since then the stock has seen a 15% rise to levels of $54 currently. However, the company’s lackluster Q4 results and 2021 guidance announced last week has weighed on IONS stock over the last few days...
August 31, 2020

Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics

CARLSBAD, Calif. and BOSTON, Aug. 31, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its affiliate Akcea Therapeutics, Inc. (NASDAQ: AKCA) today announced that they have entered into a definitive agreement under which Ionis will acquire all of the outstanding shares...
August 26, 2020

Ionis Pharmaceuticals to hold cardio-renal franchise webcast

CARLSBAD, Calif., Aug. 26, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, September 2nd at 10:00 a.m. Eastern Time to review its cardio-renal franchise. The approximately 90-minute webcast will include...
June 05, 2020

Ionis Pharmaceuticals to present at upcoming virtual investor conferences

CARLSBAD, Calif., June 5, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following virtual investor conferences: William Blair 40th Annual Growth Stock Conference...
October 29, 2019

What Caused The Sell-Off In Ionis Pharmaceuticals Stock?

Ionis Pharmaceuticals (NASDAQ: IONS), a pharma company engaged in discovering and developing RNA-targeted therapeutics, has seen its stock decline by about 11% over the last week, trading at levels of around $55 currently. The decline is possibly due to a delay in the release of data...
Show more

Ionis Pharmaceuticals Blogs

April 08, 2021

Ionis prices private placement of convertible senior notes

Ionis prices private placement of convertible senior notes Content Import Thu, 04/08/2021 - 07:05 Ionis prices private placement of convertible senior notes April 8, 2021 at 7:05 AM EDT This release is a backfill from a News Wire General …
April 06, 2021

Ionis announces proposed private placement of convertible notes

CARLSBAD, Calif. , April 6, 2021 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2026 (the "notes") in a private placement
April 05, 2021

Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS

Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS Content Import Mon, 04/05/2021 - 07:05 Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS April 5, 2021 at 7:05 AM EDT …
March 29, 2021

Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema

- IONIS-PKK-L Rx met its primary and all secondary endpoints, including a mean reduction of up to 97% in HAE attacks compared to placebo CARLSBAD, Calif. , March 29, 2021 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that data from a Phase 2 clinical study of
March 22, 2021

Ionis' partner provides update on clinical studies evaluating tominersen (IONIS-HTT Rx)

- Dosing to stop in Phase III clinical study of tominersen and paused in the open-label extension study (GEN-EXTEND) - The Phase I PK/PD study (GEN-PEAK) of tominersen and the observational Roche HD Natural History Study will continue - No new or emerging safety signals for tominersen were
March 01, 2021

Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis

Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis Content Import Mon, 03/01/2021 - 07:05 Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis March 1, 2021 at 7:05 AM EST …
Show more

 Ionis Pharmaceuticals Frequently Asked Questions

  • When was Ionis Pharmaceuticals founded?

    Ionis Pharmaceuticals was founded in 1989.

  • Who are Ionis Pharmaceuticals key executives?

    Ionis Pharmaceuticals's key executives are C. Frank Bennett, Brett P. Monia and Onaiza Cadoret-Manier.

  • How many employees does Ionis Pharmaceuticals have?

    Ionis Pharmaceuticals has 817 employees.

  • What is Ionis Pharmaceuticals revenue?

    Latest Ionis Pharmaceuticals annual revenue is $729.3 m.

  • What is Ionis Pharmaceuticals revenue per employee?

    Latest Ionis Pharmaceuticals revenue per employee is $892.6 k.

  • Who are Ionis Pharmaceuticals competitors?

    Competitors of Ionis Pharmaceuticals include Reata Pharmaceuticals, Arrowhead Pharmaceuticals and Alnylam Pharmaceuticals.

  • Where is Ionis Pharmaceuticals headquarters?

    Ionis Pharmaceuticals headquarters is located at 2855 Gazelle Ct, Carlsbad.

  • Where are Ionis Pharmaceuticals offices?

    Ionis Pharmaceuticals has an office in Carlsbad.

  • How many offices does Ionis Pharmaceuticals have?

    Ionis Pharmaceuticals has 1 office.